Identification of Selective and Potent Inhibitors of Fibroblast Activation Protein and Prolyl Oligopeptidase

被引:83
|
作者
Poplawski, Sarah E. [1 ,2 ]
Lai, Jack H. [1 ,2 ]
Li, Youhua [1 ]
Jin, Zhiping [1 ]
Liu, Yuxin [1 ]
Wu, Wengen [1 ]
Wu, Yong [1 ]
Zhou, Yuhong [1 ]
Sudmeier, James L. [1 ]
Sanford, David G. [1 ,2 ]
Bachovchin, William W. [1 ,2 ]
机构
[1] Tufts Univ, Sackler Sch Biomed Sci, Dept Biochem, Boston, MA 02111 USA
[2] Arisaph Pharmaceut Inc, Boston, MA 02110 USA
关键词
DIPEPTIDYL PEPTIDASE IV; BORONIC ACID INHIBITORS; SERINE-PROTEASE; TUMOR-GROWTH; CLEAVING ENZYME; IN-VIVO; CELLS; ENDOPEPTIDASE; POLYPEPTIDE; DEGRADATION;
D O I
10.1021/jm400351a
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Fibroblast activation protein (FAP) is a serine protease selectively expressed on reactive stromal fibroblasts of epithelial carcinomas. It is widely believed to play a role in tumor invasion and metastasis and therefore to represent a potential new drug target for cancer. Investigation into its biological function, however, has been hampered by the current unavailability of selective inhibitors. The challenge has been in identifying inhibitors that are selective for PAP over both the dipeptidyl peptidases (DPPs), with which it shares exopeptidase specificity, and prolyl oligopeptidase (PREP), with which it shares endopeptidase specificity. Here, we report the first potent FAP inhibitor with selectivity over both the DPPs and PREP, N-(pyridine-4-carbonyl)-D-Ala-boroPro (ARI-3099, 6). We also report a similarly potent and selective PREP inhibitor, N-(pyridine-3-carbonyl)-Val-boroPro (ARI-3531, 22). Both are boronic acid based inhibitors, demonstrating that high selectivity can be achieved using this electrophile. The inhibitors are stable, easy to synthesize, and should prove to be useful in helping to elucidate the biological functions of these two unique and interesting enzymes, as well as their potential as drug targets.
引用
收藏
页码:3467 / 3477
页数:11
相关论文
共 50 条
  • [31] Development and evaluation of peptide-based prolyl oligopeptidase inhibitors - Introduction of N-benzyloxycarbonyl-prolyl-3-fluoropyrrolidine as a lead in inhibitor design
    Goossens, F
    Vanhoof, G
    DeMeester, I
    Augustyns, K
    Borloo, M
    Tourwe, D
    Haemers, A
    Scharpe, S
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 250 (01): : 177 - 183
  • [32] Identification of novel, potent and selective inhibitors of Polo-like kinase 1
    Chen, Shaoqing
    Bartkovitz, David
    Cai, Jianping
    Chen, Yi
    Chen, Zhi
    Chu, Xin-Jie
    Le, Kang
    Le, Nam T.
    Luk, Kin-Chun
    Mischke, Steve
    Naderi-Oboodi, Goli
    Boylan, John F.
    Nevins, Tom
    Qing, Weiguo
    Chen, Yingsi
    Wovkulich, Peter M.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (02) : 1247 - 1250
  • [33] The role of fibroblast activation protein in health and malignancy
    Fitzgerald, Allison A.
    Weiner, Louis M.
    CANCER AND METASTASIS REVIEWS, 2020, 39 (03) : 783 - 803
  • [34] Prolyl Oligopeptidase from the Blood Fluke Schistosoma mansoni: From Functional Analysis to Anti-schistosomal Inhibitors
    Fajtova, Pavla
    Stefanic, Sasa
    Hradilek, Martin
    Dvorak, Jan
    Vondrasek, Jiri
    Jilkova, Adela
    Ulrychova, Lenka
    McKerrow, James H.
    Caffrey, Conor R.
    Mares, Michael
    Horn, Martin
    PLOS NEGLECTED TROPICAL DISEASES, 2015, 9 (06):
  • [35] Synergistic Pulmonoprotective Effect of Natural Prolyl Oligopeptidase Inhibitors in In Vitro and In Vivo Models of Acute Respiratory Distress Syndrome
    Zerikiotis, Stelios
    Efentakis, Panagiotis
    Dapola, Danai
    Agapaki, Anna
    Seiradakis, Georgios
    Kostomitsopoulos, Nikolaos
    Skaltsounis, Alexios-Leandros
    Tseti, Ioulia
    Triposkiadis, Filippos
    Andreadou, Ioanna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (18)
  • [36] Identification and characterization of potent and selective inhibitors targeting protein tyrosine phosphatase 1B (PTP1B)
    Jin, Jia
    Ye, Xiaoqing
    Boateng, Derrick
    Dai, Kaili
    Ye, Fei
    Du, Pengfei
    Yu, Han
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (16) : 2358 - 2363
  • [37] Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens
    Zhang, Jiping
    Valianou, Matthildi
    Simmons, Heidi
    Robinson, Matthew K.
    Lee, Hyung-Ok
    Mullins, Stefanie R.
    Marasco, Wayne A.
    Adams, Gregory P.
    Weiner, Louis M.
    Cheng, Jonathan D.
    FASEB JOURNAL, 2013, 27 (02) : 581 - 589
  • [38] Selective tumor targeting enabled by picomolar fibroblast activation protein inhibitors isolated from a DNA-encoded affinity maturation library
    Puglioli, Sara
    Schmidt, Eleonore
    Pellegrino, Christian
    Prati, Luca
    Oehler, Sebastian
    De Luca, Roberto
    Galbiati, Andrea
    Comacchio, Claudia
    Nadal, Lisa
    Scheuermann, Jorg
    Manz, Markus G.
    Neri, Dari
    Cazzamalli, Samuele
    Bassi, Gabriele
    Favalli, Nicholas
    CHEM, 2023, 9 (02): : 411 - 429
  • [39] Fibroblast activation protein is dispensable for control of glucose homeostasis and body weight in mice
    Panaro, Brandon L.
    Coppage, Andrew L.
    Beaudry, Jacqueline L.
    Varin, Elodie M.
    Kaur, Kirandeep
    Lai, Jack H.
    Wu, Wengen
    Liu, Yuxin
    Bachovchin, William W.
    Drucker, Daniel J.
    MOLECULAR METABOLISM, 2019, 19 : 65 - 74
  • [40] A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease
    Myohanen, T. T.
    Hannula, M. J.
    Van Elzen, R.
    Gerard, M.
    Van der Veken, P.
    Garcia-Horsman, J. A.
    Baekelandt, V.
    Mannisto, P. T.
    Lambeir, A. M.
    BRITISH JOURNAL OF PHARMACOLOGY, 2012, 166 (03) : 1097 - 1113